BHVN - NYSE

Biohaven Ltd.

BHVN·NYSE

$10.81

+6.7%

HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.14B

EPS-6.8600

P/E Ratio-1.58

Earnings Date08/10/2026

No Revenue Data

BHVN has not reported any revenue values in the available annual periods.

-738.82M

Net Income

-13%

3Y+30.0%

5Y+523.0%

10Y+40.0%

-609.44M

Operating Cash Flow

3Y+105.0%

5Y+702.0%

10Y+543.0%

Biohaven Ltd. Profit Bridge

BHVN · NYSE

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (4.14M)

Gross Profit-4.14M

Operating Expenses

Operating Expenses (741.24M)

Operating Income-745.38M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense8.00M

Pretax Income-737.38M

Income Tax (1.44M)

Net Income-738.82M

Net Income

-738.82M

Profitability Analysis

Biohaven Ltd. Income Statement

BHVN • NYSE

Biohaven Ltd. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
REVENUE
GROSS PROFIT
Cost of Revenue	(4.1M)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Gross Profit	-4.1M	0.0	0.0	0.0	0.0	0.0	0.0
OPERATING INCOME
Operating Expenses	(741.2M)	(885.1M)	(436.1M)	(567.9M)	(218.9M)	(114.5M)	(479.1M)
Selling, General & Administrative	(106.2M)	(89.2M)	(62.8M)	(130.9M)	(37.4M)	(16M)	(134.4M)
Research & Development	(635.1M)	(795.9M)	(373.3M)	(437.1M)	(181.5M)	(98.5M)	(344.7M)
Operating Income	-745.4M	-885.1M	-436.1M	-567.9M	-218.9M	-114.5M	-479.1M
PRE-TAX INCOME
Interest Expense	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-12.7M
Net Interest Income	14.6M	21.3M	17.7M	0.0	0.0	0.0	0.0
Total Other Income Expenses Net	8M	39.4M	26.5M	-1.9M	6.5M	-4.2M	-49.3M
Income Before Tax	-737.4M	-845.7M	-409.6M	-569.8M	-212.4M	-118.7M	-528.4M
NET INCOME
Income Tax Expense	(1.4M)	(735K)	-1.4M	(438K)	(1.4M)	(0.0)	(419K)
Net Income	-738.8M	-846.4M	-408.2M	-570.3M	-213.8M	-118.7M	-528.8M

SEC Filings

BHVN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 27, 2026	May 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	April 28, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 13, 2026	April 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 02, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 07, 2026	January 06, 2026	2026	View Filing

Showing 1 to 10 of 69 filings

Related Guides

Blog Categories

Continue your BHVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.